IP Library Granted Patent US 11,389,468
Granted Patent B2
US 11,389,468 · App. 16/494,581 · Granted Jul 19, 2022

Nicotinamide riboside for use in treating or preventing liver damage

Inventors: Ryan Dellinger (Azusa, CA); Santiago Roel Santos (New York, NY); Eric Marcotulli (New York, NY); Daniel A. Alminana (New York, NY); Mark Morris (New York, NY); Leonard Pershing Guarente (Newton, MA)
Assignee: Elysium Health, Inc.
A61K31/706A61K9/0053A61K31/09A61P1/16
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,389,468
App. No.
16/494,581
Granted
Jul 19, 2022
Kind
B2
Abstract

Provided herein are methods and compositions related to treating and/or preventing liver related diseases and disorders and for improving liver health in a subject by administering to the subject (e.g., orally administering to the subject) a composition comprising nicotinamide riboside and/or pterostilbene.

Claims (10)

1. A method of decreasing the serum level of alanine transaminase (ALT) or aspartate transaminase (AST) in a subject comprising administering to the subject a composition comprising nicotinamide riboside and pterostilbene, wherein each dose of the composition comprises 250 mg of nicotinamide riboside and 50 mg pterostilbene.

2. The method of claim 1 , wherein the serum level of ALT or AST is decreased in the subject by at least 0.5 U/L after administration of the composition.

3. The method of claim 1 , wherein the administration of the composition comprises administering one or more doses of the composition.

4. The method of claim 3 , wherein each dose is administered at least once a week and wherein the one or more doses are administered for at least 7 days.

5. The method of claim 1 , wherein the composition is formulated as a pill, a tablet, or a capsule.

6. The method of claim 1 , wherein the composition is administered orally.

7. The method of claim 1 , wherein the composition is self-administered.

8. The method of claim 3 , wherein each dose is administered at least once a day.

9. The method of claim 3 , wherein the one or more doses are administered for at least 2 months.

10. The method of claim 3 , wherein the one or more doses are administered for at least 6 months.

Assignments (2)
SECURITY INTEREST Recorded May 28, 2021
From: ELYSIUM HEALTH, INC.
To: VENTURE LENDING & LEASING IX, INC.
Reel/Frame 056388/0978 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 17, 2020
From: DELLINGER, RYAN; ROEL SANTOS, SANTIAGO; MARCOTULLI, ERIC A.; ALMINANA, DANIEL A.; MORRIS, MARK; PERSHING GUARENTE, LEONARD
To: ELYSIUM HEALTH, INC.
Reel/Frame 052427/0410 →
Continuity (2)
Provisional Application 62472883 · Mar 17, 2017
Related Publication 20210205342A1 · Jul 8, 2021
Cited By (1)
US 12,649,760